

# Hui-Wen Lo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2721238/publications.pdf>

Version: 2024-02-01

89  
papers

7,130  
citations

66343

42  
h-index

56724

83  
g-index

91  
all docs

91  
docs citations

91  
times ranked

10595  
citing authors

#	ARTICLE	IF	CITATIONS
1	Brain metastasis prognostic nomograms and brain metastasis velocity: a narrative review. <i>Chinese Clinical Oncology</i> , 2022, 11, 10-10.	1.2	1
2	NEDD4 degrades TUSC2 to promote glioblastoma progression. <i>Cancer Letters</i> , 2022, 531, 124-135.	7.2	6
3	Local control outcomes for combination of stereotactic radiosurgery and immunotherapy for non-small cell lung cancer brain metastases. <i>Journal of Neuro-Oncology</i> , 2022, 157, 101-107.	2.9	19
4	IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 866014.	2.8	87
5	Breast cancer extracellular vesicles-derived miR-1290 activates astrocytes in the brain metastatic microenvironment via the FOXA2 <sup>+</sup> CNTF axis to promote progression of brain metastases. <i>Cancer Letters</i> , 2022, 540, 215726.	7.2	24
6	TrkA Interacts with and Phosphorylates STAT3 to Enhance Gene Transcription and Promote Breast Cancer Stem Cells in Triple-Negative and HER2-Enriched Breast Cancers. <i>Cancers</i> , 2021, 13, 2340.	3.7	5
7	Abstract 1979: JAK2/STAT3 and TrkA pathways are frequently co-activated in triple-negative and HER2-enriched breast cancers and the co-activation correlates with an increased potential of metastasis. , 2021, , .		0
8	BSCI-14. tGLI1 is an actionable therapeutic target in breast cancer brain metastases. <i>Neuro-Oncology Advances</i> , 2021, 3, iii4-iii4.	0.7	0
9	Transgenic mouse models of breast cancer. <i>Cancer Letters</i> , 2021, 516, 73-83.	7.2	7
10	TGLI1 transcription factor mediates breast cancer brain metastasis via activating metastasis-initiating cancer stem cells and astrocytes in the tumor microenvironment. <i>Oncogene</i> , 2020, 39, 64-78.	5.9	64
11	54. tGLI1 IS AN ACTIONABLE THERAPEUTIC TARGET IN BREAST CANCER BRAIN METASTASES. <i>Neuro-Oncology Advances</i> , 2020, 2, ii11-ii11.	0.7	0
12	Her2 promotes early dissemination of breast cancer by suppressing the p38 pathway through Skp2-mediated proteasomal degradation of Tpl2. <i>Oncogene</i> , 2020, 39, 7034-7050.	5.9	6
13	Exosomal MicroRNAs and Organotropism in Breast Cancer Metastasis. <i>Cancers</i> , 2020, 12, 1827.	3.7	36
14	Hedgehog Signaling and Truncated GLI1 in Cancer. <i>Cells</i> , 2020, 9, 2114.	4.1	97
15	Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis. <i>Oncogene</i> , 2020, 39, 6589-6605.	5.9	50
16	Predictors of Adverse Radiation Effect in Brain Metastasis Patients Treated With Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 295-303.	0.8	20
17	LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 31-41.	2.5	13
18	Multi-Omics Analysis of Brain Metastasis Outcomes Following Craniotomy. <i>Frontiers in Oncology</i> , 2020, 10, 615472.	2.8	29

#	ARTICLE	IF	CITATIONS
19	BSCI-13. TUMOR-SPECIFIC tGLI1 TRANSCRIPTION FACTOR MEDIATES BREAST CANCER BRAIN METASTASIS VIA ACTIVATING METASTASIS-INITIATING CANCER STEM CELLS AND ASTROCYTES IN THE TUMOR MICROENVIRONMENT. <i>Neuro-Oncology Advances</i> , 2019, 1, i3-i3.	0.7	0
20	CD138 plasma cells may predict brain metastasis recurrence following resection and stereotactic radiosurgery. <i>Scientific Reports</i> , 2019, 9, 14385.	3.3	4
21	Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer. <i>Cancer Letters</i> , 2019, 448, 11-19.	7.2	47
22	Elevated leptin disrupts epithelial polarity and promotes premalignant alterations in the mammary gland. <i>Oncogene</i> , 2019, 38, 3855-3870.	5.9	38
23	Ca <sup>2+</sup> and CACNA1H mediate targeted suppression of breast cancer brain metastasis by AM RF EMF. <i>EBioMedicine</i> , 2019, 44, 194-208.	6.1	45
24	Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 553-566.	2.5	51
25	Identification of CD37, cystatin A, and IL-23A gene expression in association with brain metastasis: analysis of a prospective trial. <i>International Journal of Biological Markers</i> , 2019, 34, 90-97.	1.8	10
26	Trk receptor tyrosine kinases in metastasis and cancer therapy. <i>Discovery Medicine</i> , 2019, 28, 195-203.	0.5	4
27	Truncated Glioma-Associated Oncogene Homolog 1 (tGLI1) Mediates Mesenchymal Glioblastoma via Transcriptional Activation of CD44. <i>Cancer Research</i> , 2018, 78, 2589-2600.	0.9	26
28	Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer. <i>Oncogene</i> , 2018, 37, 2502-2514.	5.9	69
29	Staged Stereotactic Radiosurgery for Large Brain Metastases: Local Control and Clinical Outcomes of a One-Two Punch Technique. <i>Neurosurgery</i> , 2018, 83, 114-121.	1.1	48
30	The number of prior lines of systemic therapy as a prognostic factor for patients with brain metastases treated with stereotactic radiosurgery: Results of a large single institution retrospective analysis. <i>Clinical Neurology and Neurosurgery</i> , 2018, 165, 24-28.	1.4	3
31	Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 813-819.	1.3	9
32	Use of non-ionizing electromagnetic fields for the treatment of cancer. <i>Frontiers in Bioscience - Landmark</i> , 2018, 23, 284-297.	3.0	22
33	Inhibiting TRK Proteins in Clinical Cancer Therapy. <i>Cancers</i> , 2018, 10, 105.	3.7	133
34	Loss of XIST in Breast Cancer Activates MSN-c-Met and Reprograms Microglia via Exosomal miRNA to Promote Brain Metastasis. <i>Cancer Research</i> , 2018, 78, 4316-4330.	0.9	233
35	Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns?. <i>Neuroradiology</i> , 2018, 60, 1043-1051.	2.2	15
36	Potential prognostic markers for survival and neurologic death in patients with breast cancer brain metastases who receive upfront SRS alone. <i>Journal of Radiosurgery and SBRT</i> , 2018, 5, 277-283.	0.2	5

#	ARTICLE	IF	CITATIONS
37	Leptomeningeal failure in patients with breast cancer receiving stereotactic radiosurgery for brain metastases. <i>Journal of Clinical Neuroscience</i> , 2017, 43, 6-10.	1.5	8
38	Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth. <i>Oncotarget</i> , 2017, 8, 73947-73963.	1.8	33
39	Survival and Failure Outcomes Predicted by Brain Metastasis Volumetric Kinetics in Melanoma Patients Following Upfront Treatment with Stereotactic Radiosurgery Alone. <i>Cureus</i> , 2017, 9, e1934.	0.5	4
40	Stereotactic radiosurgery in the treatment of brain metastases from gynecologic primary cancer. <i>Journal of Radiosurgery and SBRT</i> , 2017, 5, 55-61.	0.2	2
41	Tumor suppressor candidate 2 (TUSC2, FUS-1) and human cancers. <i>Discovery Medicine</i> , 2017, 23, 325-330.	0.5	16
42	EGFR and HER2 signaling in breast cancer brain metastasis. <i>Frontiers in Bioscience - Elite</i> , 2016, 8, 245-263.	1.8	51
43	Biology and treatment of metastasis of sarcoma to the brain. <i>Frontiers in Bioscience - Elite</i> , 2016, 8, 233-244.	1.8	9
44	Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothed and GLI Inhibitors. <i>Cancers</i> , 2016, 8, 22.	3.7	476
45	EGFR and HER2 signaling in breast cancer brain metastasis. <i>Frontiers in Bioscience - Elite</i> , 2016, 8, 245-263.	1.8	30
46	Activation of the c-Met Pathway Mobilizes an Inflammatory Network in the Brain Microenvironment to Promote Brain Metastasis of Breast Cancer. <i>Cancer Research</i> , 2016, 76, 4970-4980.	0.9	102
47	Impact of timing of radiotherapy in patients with newly diagnosed glioblastoma. <i>Clinical Neurology and Neurosurgery</i> , 2016, 151, 73-78.	1.4	18
48	Mechanisms regulating glioma invasion. <i>Cancer Letters</i> , 2015, 362, 1-7.	7.2	269
49	The gain-of-function GLI1 transcription factor TGLI1 enhances expression of VEGF-C and TEM7 to promote glioblastoma angiogenesis. <i>Oncotarget</i> , 2015, 6, 22653-22665.	1.8	46
50	STAT3 Target Genes Relevant to Human Cancers. <i>Cancers</i> , 2014, 6, 897-925.	3.7	398
51	The GLI1 splice variant TGLI1 promotes glioblastoma angiogenesis and growth. <i>Cancer Letters</i> , 2014, 343, 51-61.	7.2	45
52	STAT1 gene expression is enhanced by nuclear EGFR and HER2 via cooperation With STAT3. <i>Molecular Carcinogenesis</i> , 2013, 52, 959-969.	2.7	57
53	Akt destabilizes p57Kip2: Akt at the converging crossroad?. <i>Cell Cycle</i> , 2013, 12, 870-871.	2.6	2
54	Regulation of Apoptosis by HER2 in Breast Cancer. <i>Journal of Carcinogenesis &amp; Mutagenesis</i> , 2013, 2013, .	0.3	48

#	ARTICLE	IF	CITATIONS
55	HER2 Phosphorylates and Destabilizes Pro-Apoptotic PUMA, Leading to Antagonized Apoptosis in Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e78836.	2.5	16
56	TGLI1 Upregulates Expression of VEGFR2 and VEGF-A, Leading to a Robust VEGF-VEGFR2 Autocrine Loop and Cancer Cell Growth. <i>Cancer Hallmarks</i> , 2013, 1, 28-37.	0.8	10
57	Identification, Functional Characterization, and Pathobiological Significance of GLI1 Isoforms in Human Cancers. <i>Vitamins and Hormones</i> , 2012, 88, 115-140.	1.7	23
58	Landscape of EGFR signaling network in human cancers: Biology and therapeutic response in relation to receptor subcellular locations. <i>Cancer Letters</i> , 2012, 318, 124-134.	7.2	205
59	Upregulation of VEGF-A and CD24 gene expression by the tGLI1 transcription factor contributes to the aggressive behavior of breast cancer cells. <i>Oncogene</i> , 2012, 31, 104-115.	5.9	111
60	M-HIFU Inhibits Tumor Growth, Suppresses STAT3 Activity and Enhances Tumor Specific Immunity in a Transplant Tumor Model of Prostate Cancer. <i>PLoS ONE</i> , 2012, 7, e41632.	2.5	49
61	Dacomitinib, an emerging HER-targeted therapy for non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2012, 4, 639-42.	1.4	11
62	Hedgehog pathway and GLI1 isoforms in human cancer. <i>Discovery Medicine</i> , 2012, 13, 105-13.	0.5	79
63	EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocation: A potential mechanism of EGFR-driven antagonism of apoptosis. <i>Molecular Cancer</i> , 2011, 10, 26.	19.2	68
64	The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases. <i>Current Genomics</i> , 2010, 11, 238-245.	1.6	63
65	EGFR-Targeted Therapy in Malignant Glioma: Novel Aspects and Mechanisms of Drug Resistance. <i>Current Molecular Pharmacology</i> , 2010, 3, 37-52.	1.5	116
66	Cyclooxygenase-2 Is a Novel Transcriptional Target of the Nuclear EGFR-STAT3 and EGFRvIII-STAT3 Signaling Axes. <i>Molecular Cancer Research</i> , 2010, 8, 232-245.	3.4	163
67	Targeting Ras-RAF-ERK and its Interactive Pathways as a Novel Therapy for Malignant Gliomas. <i>Current Cancer Drug Targets</i> , 2010, 10, 840-848.	1.6	82
68	Editorial [Hot topic: Emerging Therapeutic Targets and Agents for Glioblastoma Therapy – Part II (Guest Editor: Hui-Wen Lo)]. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2010, 10, 511-511.	1.7	0
69	EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocation of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity. <i>Cancer Letters</i> , 2010, 294, 101-110.	7.2	55
70	Nuclear mode of the EGFR signaling network: biology, prognostic value, and therapeutic implications. <i>Discovery Medicine</i> , 2010, 10, 44-51.	0.5	60
71	A Novel Splice Variant of <i>GLI1</i> That Promotes Glioblastoma Cell Migration and Invasion. <i>Cancer Research</i> , 2009, 69, 6790-6798.	0.9	134
72	Identification and Functional Characterization of the Human <i>Glutathione S-Transferase P1</i> Gene as a Novel Transcriptional Target of the <i>p53</i> Tumor Suppressor Gene. <i>Molecular Cancer Research</i> , 2008, 6, 843-850.	3.4	50

#	ARTICLE	IF	CITATIONS
73	Constitutively Activated STAT3 Frequently Coexpresses with Epidermal Growth Factor Receptor in High-Grade Gliomas and Targeting STAT3 Sensitizes Them to Iressa and Alkylators. <i>Clinical Cancer Research</i> , 2008, 14, 6042-6054.	7.0	226
74	Epidermal Growth Factor Receptor Cooperates with Signal Transducer and Activator of Transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of <i>Twist</i> Gene Expression. <i>Cancer Research</i> , 2007, 67, 9066-9076.	0.9	605
75	Genetic polymorphism and function of glutathione S-transferases in tumor drug resistance. <i>Current Opinion in Pharmacology</i> , 2007, 7, 367-374.	3.5	188
76	Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. <i>British Journal of Cancer</i> , 2006, 94, 184-188.	6.4	254
77	EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocation. <i>Breast Cancer Research and Treatment</i> , 2006, 95, 211-218.	2.5	209
78	Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin $\beta 1$ and CRM1. <i>Journal of Cellular Biochemistry</i> , 2006, 98, 1570-1583.	2.6	210
79	Co-regulation of <i>Myb</i> expression by E2F1 and EGF receptor. <i>Molecular Carcinogenesis</i> , 2006, 45, 10-17.	2.7	157
80	Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. <i>Cancer Cell</i> , 2005, 7, 575-589.	16.8	463
81	Cancer-specific Gene Therapy. <i>Advances in Genetics</i> , 2005, 54, 233-255.	1.8	59
82	Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. <i>Cancer Research</i> , 2005, 65, 338-48.	0.9	199
83	Selective Activation of Ceruloplasmin Promoter in Ovarian Tumors. <i>Cancer Research</i> , 2004, 64, 1788-1793.	0.9	32
84	The Human Glutathione S-Transferase P1 Protein Is Phosphorylated and Its Metabolic Function Enhanced by the Ser/Thr Protein Kinases, cAMP-Dependent Protein Kinase and Protein Kinase C, in Glioblastoma Cells. <i>Cancer Research</i> , 2004, 64, 9131-9138.	0.9	54
85	Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. <i>Cancer Cell</i> , 2004, 6, 251-261.	16.8	261
86	Cyclic AMP mediated GSTP1 gene activation in tumor cells involves the interaction of activated CREB-1 with the GSTP1 CRE: A novel mechanism of cellular GSTP1 gene regulation. <i>Journal of Cellular Biochemistry</i> , 2002, 87, 103-116.	2.6	15
87	Structure of the human allelic glutathione S-transferase- $\pi$ gene variant, hGSTP1* <i>C</i> , cloned from a glioblastoma multiforme cell line. <i>Chemico-Biological Interactions</i> , 1998, 111-112, 91-102.	4.0	19
88	Genomic Cloning of hGSTP1* <i>C</i> , an Allelic Human Pi Class Glutathione S-Transferase Gene Variant and Functional Characterization of Its Retinoic Acid Response Elements. <i>Journal of Biological Chemistry</i> , 1997, 272, 32743-32749.	3.4	38
89	Clinical Outcomes of Dose Escalated Re-Irradiation in Patients with Recurrent High Grade Glioma. <i>Neuro-Oncology Practice</i> , 0, , .	1.6	1